Scarica l'app Stockscreener
23.52
7.59%
1.66
Pre-mercato:
25.00
1.48
+6.29%
Anaptysbio Inc Borsa (ANAB) Ultime notizie
Squarepoint Ops LLC Has $1.07 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering - Investing.com India
Transcript : AnaptysBio, Inc.Special Call - marketscreener.com
AnaptysBio Reports Positive Phase 2b Trial Results - TipRanks
AnaptysBio Reports Durable Responses, Favorable Safety for Rosnilimab in Arthritis Trial - marketscreener.com
AnaptysBio (ANAB) Reports Promising Results for Rosnilimab in Rheumatoid Arthritis | ANAB Stock News - GuruFocus
AnaptysBio reports promising Phase 2b trial results for RA drug - Investing.com Australia
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA - marketscreener.com
AnaptysBio reports promising Phase 2b trial results for RA drug By Investing.com - Investing.com Nigeria
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA | ANAB Stock News - GuruFocus
Millennium Management LLC Sells 185,049 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $199,000 Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Deutsche Bank AG Purchases 6,113 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
AnaptysBio (NASDAQ:ANAB) Shares Gap Up After Analyst Upgrade - MarketBeat
Voloridge Investment Management LLC Sells 85,708 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Two Sigma Investments LP Buys 140,457 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Receives Buy Rating from Guggenheim - MarketBeat
Trading (ANAB) With Integrated Risk Controls - news.stocktradersdaily.com
AnaptysBio (NASDAQ:ANAB) Trading Up 6.6%What's Next? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given Outperform Rating at Wedbush - MarketBeat
Woodline Partners LP Purchases 25,094 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Two Sigma Advisers LP Has $3.88 Million Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Earns Buy Rating from Guggenheim - Defense World
Northern Trust Corp Grows Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $90.00 at Guggenheim - Defense World
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade - Defense World
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock - Benzinga
AnaptysBio (ANAB) Maintains Buy Rating with Raised Price Target | ANAB Stock News - GuruFocus
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday - Benzinga
Guggenheim raises AnaptysBio stock target to $90, maintains Buy By Investing.com - Investing.com India
Guggenheim raises AnaptysBio stock target to $90, maintains Buy - Investing.com
AnaptysBio, Inc. (NASDAQ:ANAB) Position Lessened by BNP Paribas Financial Markets - Defense World
AnaptysBio (ANAB) Sees Price Target Uplift Amid Positive Developments | ANAB Stock News - GuruFocus
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilim - GuruFocus
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 | ANAB Stock News - GuruFocus
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 - The Manila Times
AnaptysBio to Host Investor Call for Phase 2b RENOIR Trial Data on Rosnilimab for Rheumatoid Arthritis - Nasdaq
Anaptys to Announce Updated Data from Phase 2b Trial of - GlobeNewswire
New PD-1 Drug Trial Data: Rosnilimab Shows Promise for Rheumatoid Arthritis TreatmentKey Results Coming - Stock Titan
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Rafferty Asset Management LLC - MarketBeat
Frazier Life Sciences Management L.P. Sells 635,470 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by D. E. Shaw & Co. Inc. - MarketBeat
Soleus Capital Management L.P. Takes Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Graham Capital Management L.P. Buys New Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Northern Trust Corp Boosts Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Dimensional Fund Advisors LP Decreases Position in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Sanofi Acquires New Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Jacobs Levy Equity Management Inc. Boosts Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
Wolfe Research maintains Outperform on AnaptysBio shares, $25 target By Investing.com - Investing.com UK
0.87%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):